Table 1 The demographic characteristics, comorbidities, sites of involvement, pathogenic fungi, and outcomes of the patients with IFRS
From: Invasive fungal rhinosinusitis, clinical manifestations, and prognostic values: as case series audit
No | Age (years)/gender | Comorbid condition | Orbital involvement | Intracranial involvement | Cranial nerve palsy | Hard palate involvement | Pathogenic fungus | Outcome |
|---|---|---|---|---|---|---|---|---|
1 | 16/M | ALL | − | − | − | + | Trichosporon Ashaii | Died |
2 | 11/M | ALL | − | − | − | − | Mucormycetes | Died |
3 | 7/M | ALL | − | − | − | − | Aspergillus | Died |
4 | 70/K | AML | + | + | − | − | Aspergillus | Died |
5 | 18/M | AML | + (Bilateral) | + | II, III | + | Mucormycetes | Died |
6 | 54/M | DM | + | + | III, IV, V, VI | − | Mucormycetes | Died |
7 | 71/M | DM | + | + | II, III, IV, VI, VII | + | Mucormycetes | Died |
8 | 61/F | DM | − | − | − | − | Aspergillus | Survived |
9 | 85/M | DM | + | + | − | − | Mucormycetes | Died |
10 | 54/M | DM | + | + | II, VII | + | Mucormycetes | Died |
11 | 57/M | DM | + | + | IV, VI, VII | − | Mucormycetes | Survived |
12 | 50/F | DM | + | + | − | + | Mucormycetes | Died |
13 | 49/F | DM | + | + | II, III, IV, V, VI, VII | + | Mucormycetes | Survived |
14 | 20/M | DM (Type 1) | − | − | VII | − | Mukormikozis | Survived |
15 | 51/F | DM, AML | + | + | − | − | Aspergillus | Died |
16 | 66/F | DM, COVID-19 | - | + | − | − | Mucormycetes | Survived |
17 | 68/F | Metastatic thyroid medullary carcinoma | − | − | − | − | Mucormycetes | Survived |
18 | 48/F | Pre B ALL | − | − | − | + | Aspergillus | Died |
19 | 10/M | Pre B ALL | − | − | − | + | Mucormycetes | Survived |
20 | 51/F | Renal transplantation | + | + | II, III, IV, V, VI | + | Mucormycetes | Died |